{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:01:55Z","timestamp":1785859315830,"version":"3.56.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NSW Ministry of Health","award":["dBC2531"],"award-info":[{"award-number":["dBC2531"]}]},{"name":"NSW Ministry of Health","award":["dBC2531"],"award-info":[{"award-number":["dBC2531"]}]},{"name":"NSW Ministry of Health","award":["dBC2531"],"award-info":[{"award-number":["dBC2531"]}]},{"name":"NSW Ministry of Health","award":["dBC2531"],"award-info":[{"award-number":["dBC2531"]}]},{"name":"NSW Ministry of Health","award":["dBC2531"],"award-info":[{"award-number":["dBC2531"]}]},{"name":"NSW Ministry of Health","award":["dBC2531"],"award-info":[{"award-number":["dBC2531"]}]},{"name":"NSW Ministry of Health","award":["dBC2531"],"award-info":[{"award-number":["dBC2531"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In 2019 daily liquid methadone and sublingual buprenorphine-naloxone were primary opioid agonist treatments for correctional centres in New South Wales, Australia. However, both had significant potential for diversion to other patients, and their daily administration was resource intensive. An alternative treatment in the form of subcutaneous depot buprenorphine became a viable option following a safety trial in 2020 \u2013 the UNLOC-T study. Depot preparation demonstrated advantages over current treatments as more difficult to divert and requiring fewer administrations. This paper reports the results of economic modelling of staffing costs in medication administration comparing depot buprenorphine, methadone, and sublingual buprenorphine provision in UNLOC-T trial facilities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The costing study adopted a micro-costing approach involving the synthesis of cost data from the UNLOC-T clinical trial as well as data collected from Justice Health and Forensic Mental Health Network records. Labour and materials data were collected during site observations and interviews. Costs were calculated from two payer perspectives: a) the New South Wales (state) government which funds custodial and health services; and b) the Australian Commonwealth government, which pays for medications. The analysis compared the monthly-per-patient cost for each of the three medications in trial-site facilities during July 2019. This was followed by simulation of depot buprenorphine implementation across the study population. Costs associated with medical assessment and reviews were excluded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The monthly-per-patient New South Wales government service costs of depot buprenorphine, methadone and sublingual buprenorphine were: $151, $379 and $1,529 respectively while Commonwealth government medication costs were $434, $80 and $525. The implementation simulation found that service costs of depot buprenorphine declined as patients transitioned from weekly to monthly administration. Costs of treatment using the other medications increased as patient numbers decreased alongside fixed costs. At 12\u00a0months, monthly-per-patient service costs for depot buprenorphine, methadone and sublingual buprenorphine\u2014which would be completely phased out by month 13\u2014were $92, $530 and $2,162 respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Depot buprenorphine was consistently the least costly of the treatment options. Future modelling could allow for dynamic patient populations and downstream impacts for participants and the state health system.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=12618000942257\">ACTRN12618000942257<\/jats:ext-link>. Registered 4 June 2018.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12913-022-08687-8","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T15:48:33Z","timestamp":1667922513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model"],"prefix":"10.1186","volume":"22","author":[{"given":"R.","family":"Ling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cretikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. V.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. S.","family":"Haber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Lintzeris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"Dunlop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Searles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"key":"8687_CR1","doi-asserted-by":"publisher","unstructured":"Larney S, Gisev N, Farrell M, Dobbins T, Burns L, Gibson A, Kimber J, Degenhardt L. Opioid substitution therapy as a strategy to reduce deaths in prison: Retrospective cohort study.\u00a0BMJ Open.\u00a02014;4(4):e004666.\u00a0https:\/\/doi.org\/10.1136\/bmjopen-2013-004666.","DOI":"10.1136\/bmjopen-2013-004666"},{"issue":"8","key":"8687_CR2","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/add.13779","volume":"112","author":"J Marsden","year":"2017","unstructured":"Marsden J, Stillwell G, Jones H, Cooper A, Eastwood B, Farrell M, Lowden T, Maddalena N, Metcalfe C, Shaw J, et al. Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England. Addiction. 2017;112(8):1408\u201318.","journal-title":"Addiction"},{"key":"8687_CR3","volume-title":"European Drug Report 2019","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2019","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2019. Luxembourg: Trends and Developments; 2019."},{"key":"8687_CR4","unstructured":"Harm Reduction International: Global State of Harm Reductions: 2019 updates; 2019[https:\/\/www.hri.global\/global-state-of-harm-reduction-2019] Accessed: 15 Dec 2020."},{"issue":"6","key":"8687_CR5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.drugpo.2006.11.015","volume":"18","author":"A Stallwitz","year":"2007","unstructured":"Stallwitz A, Stover H. The impact of substitution treatment in prisons\u2013a literature review. Int J Drug Policy. 2007;18(6):464\u201374.","journal-title":"Int J Drug Policy"},{"key":"8687_CR6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drugalcdep.2016.11.032","volume":"171","author":"Z Bi-Mohammed","year":"2017","unstructured":"Bi-Mohammed Z, Wright NM, Hearty P, King N, Gavin H. Prescription opioid abuse in prison settings: A systematic review of prevalence, practice and treatment responses. Drug Alcohol Depend. 2017;171:122\u201331.","journal-title":"Drug Alcohol Depend"},{"key":"8687_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.drugalcdep.2014.05.011","volume":"142","author":"MS Gordon","year":"2014","unstructured":"Gordon MS, Kinlock TW, Schwartz RP, Fitzgerald TT, O\u2019Grady KE, Vocci FJ. A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug Alcohol Depend. 2014;142:33\u201340.","journal-title":"Drug Alcohol Depend"},{"key":"8687_CR8","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.drugalcdep.2014.09.775","volume":"144","author":"NMJ Wright","year":"2014","unstructured":"Wright NMJ, Mohammed Z, Hughes G. Comparative prices of diverted buprenorphine\/naloxone and buprenorphine in a UK prison setting: a cross-sectional survey of drug using prisoners. Drug Alcohol Depend. 2014;144:254\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"8687_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/dar.12317","volume":"35","author":"N White","year":"2016","unstructured":"White N, Ali R. B L, Zador D, Mattick RP, Degenhardt L: The extramedical use and diversion of opioid substitution medications and other medications in prison settings in Australia following the introduction of buprenorphine\u2013naloxone film. Drug Alcohol Rev. 2016;35(1):76\u201382.","journal-title":"Drug Alcohol Rev"},{"key":"8687_CR10","unstructured":"Australian Institute of Health and Welfare: National Opioid Pharmacotherapy Statistics Annual Data Collection (NOPSAD) 2018 Canberra AIHW; 2019[https:\/\/www.aihw.gov.au\/about-our-data\/our-data-collections\/nopsad-collection] Accessed: 1 Jul 2020."},{"key":"8687_CR11","unstructured":"Australian Bureau of Statistics: Prisoner Characteristics, Australia Canberra, ACT, Australia Australian Bureau of Statistics; 2019[https:\/\/www.abs.gov.au\/statistics\/people\/crime-and-justice\/prisoners-australia\/2019] Accessed: 19 Jan 2021."},{"key":"8687_CR12","unstructured":"Therapeutic Goods Administration: AusPAR: Buprenorphine: Australian Public Assessment Report Therapeutic Goods Administration; 2021[https:\/\/www.tga.gov.au\/auspar\/auspar-buprenorphine-0] Accessed: 10 Feb 2020."},{"key":"8687_CR13","unstructured":"Therapeutic Goods Administration: Public Summary: SUBLOCADE buprenorphine 300 mg\/1.5 mL modified release solution for injection pre-filled syringe (with needle) Canberra, NSW: Therapeutic Goods Administration; 2022[https:\/\/www.ebs.tga.gov.au\/servlet\/xmlmillr6?dbid=ebs\/PublicHTML\/pdfStore.nsf&docid=12039C4C3D5690EBCA25887C00425AAC&agid=(PrintDetailsPublic)&actionid=1] Accessed: 8 Aug 2022."},{"key":"8687_CR14","unstructured":"TGA eBS: Australian Product Information - Sublocade\u00ae: Indivior Pty Ltd;; 2019[https:\/\/www.ebs.tga.gov.au] Accessed: 2 Jul 2022."},{"issue":"8","key":"8687_CR15","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/add.14636","volume":"114","author":"M Frost","year":"2019","unstructured":"Frost M, Bailey GL, Lintzeris N, Strang J, Dunlop A, Nunes EV, Jansen JB, Frey LC, Weber B, Haber P, et al. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder. Addiction. 2019;114(8):1416\u201326.","journal-title":"Addiction"},{"key":"8687_CR16","doi-asserted-by":"publisher","unstructured":"Lintzeris N, Dunlop AJ, Haber PS, Lubman DI, Graham R, Hutchinson S, Arunogiri S, Hayes V, Hjelmstr\u00f6m P, Svedberg A et al. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial. JAMA Netw Open.\u00a02021;4(5):e219041. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.9041.","DOI":"10.1001\/jamanetworkopen.2021.9041"},{"issue":"2","key":"8687_CR17","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/add.15627","volume":"117","author":"AJ Dunlop","year":"2021","unstructured":"Dunlop AJ, White B, Roberts J, Cretikos M, Attalla D, Ling R, Searles A, Mackson J, Doyle MF, McEntyre E, et al. Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings. Addiction. 2021;117(2):382\u201391.","journal-title":"Addiction"},{"key":"8687_CR18","unstructured":"Doran C. Economic Evaluation of Interventions for Illicit Opioid Dependence: a review of evidence. In: Third Meeting of Technical Development Group (Tdg) for the Who \"Guidelines For Psychosocially Assisted Pharmacotherapy Of Opioid Dependence\". Geneva, Switzerland; 2007."},{"key":"8687_CR19","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1080\/13696998.2017.1341416","volume":"20","author":"JA Carter","year":"2017","unstructured":"Carter JA, Dammerman R, Frost M. Cost-effectiveness of Subdermal Implantable Buprenorphine Versus Sublingual Buprenorphine to Treat Opioid Use Disorder. J Med Econ. 2017;20:893\u2013901.","journal-title":"J Med Econ"},{"key":"8687_CR20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2147\/CEOR.S242984","volume":"12","author":"H Phillips-Jackson","year":"2020","unstructured":"Phillips-Jackson H, Hallam C, Cullen N, Pearson T, Gilman M, Li L, Musgrave P. Budget Impact Analysis of the Introduction of Injectable Prolonged-Release Buprenorphine on Opioid Use Disorder Care Resource Requirements. Clinicoecon Outcomes Res. 2020;12:233\u201340.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"6","key":"8687_CR21","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/00952990.2018.1491048","volume":"44","author":"BP Horn","year":"2018","unstructured":"Horn BP, Li X, Mamun S, McCrady B, French MT. The economic costs of jail-based methadone maintenance treatment. Am J Drug Alcohol Abuse. 2018;44(6):611\u20138.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"2","key":"8687_CR22","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.drugalcdep.2006.01.010","volume":"84","author":"E Warren","year":"2006","unstructured":"Warren E, Viney R, Shearer J, Shanahan M, Wodak A, Dolan K. Value for money in drug treatment: economic evaluation of prison methadone. Drug Alcohol Depend. 2006;84(2):160\u20136.","journal-title":"Drug Alcohol Depend"},{"key":"8687_CR23","unstructured":"Australian Bureau of Statistics: Consumer Price Index, Australia, December 2021 Canberra, Australia: Publisher, 2021[https:\/\/www.abs.gov.au\/statistics\/economy\/price-indexes-and-inflation\/consumer-price-index-australia\/dec-2021] Accessed: 29 Nov 2019."},{"key":"8687_CR24","unstructured":"Reserve Bank of Australia: Historical Daily Exchange Rates Canberra: Publisher, 2019[https:\/\/www.rba.gov.au\/statistics\/tables\/xls-hist\/f11hist.xls] Accessed: 2 Jan 2022."},{"key":"8687_CR25","unstructured":"Corben S, Tang H: NSW Inmate Census 2019 Sydney, NSW: Corrective Services NSW; 2020[https:\/\/www.correctiveservices.dcj.nsw.gov.au\/documents\/research-and-statistics\/sp48-nsw-inmate-census-2019.pdf] Accessed."},{"key":"8687_CR26","volume-title":"LJ: Applied Methods of Cost-Benefit Analysis in Health Care","year":"2010","unstructured":"McIntosh E, Clarke P, Frew E, editors. LJ: Applied Methods of Cost-Benefit Analysis in Health Care. Oxford: Oxford; 2010."},{"key":"8687_CR27","unstructured":"Corrective Services NSW: Corrective Services NSW (Home Page); 2021[https:\/\/www.correctiveservices.justice.nsw.gov.au\/] Accessed: 12 Nov 2020."},{"key":"8687_CR28","unstructured":"Justice Health and Forensic Mental Health Network: Snap Shot NSW Prison Opioid Agonist Treatment Patients (August 2018 to July 2019) Rod Ling 2019."},{"key":"8687_CR29","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"GL S: Methods for the Economic Evaluation of Health Care Programs","author":"MF Drummond","year":"2005","unstructured":"Drummond MF, Sculpher MJ, Torrance GW, O\u2019Brien BJ. GL S: Methods for the Economic Evaluation of Health Care Programs. 3rd ed. Oxford, UK: Oxford University Press; 2005.","edition":"3"},{"key":"8687_CR30","doi-asserted-by":"publisher","DOI":"10.2307\/j.ctvc77fb7","volume-title":"Economics in Two Lessons: Why Markets Work So Well and Why They Can Fail So Badly","author":"J Quiggin","year":"2019","unstructured":"Quiggin J. Economics in Two Lessons: Why Markets Work So Well and Why They Can Fail So Badly. Princeton, New Jersey: Princeton University Press; 2019."},{"key":"8687_CR31","unstructured":"Industrial Relations Commission of New South Wales: Public Health System Nurses' and Midwives' (state) Award 2021. 2021 [https:\/\/www.health.nsw.gov.au\/careers\/conditions\/Awards\/nurses.pdf] Accessed: 19 Feb 2022."},{"key":"8687_CR32","unstructured":"Industrial Relations Commission of New South Wales: Crown Employees (Public Sector - Salaries 2021) Award 2021 [https:\/\/psa.asn.au\/wp-content\/uploads\/2021\/07\/Crown-Employees-Public-Sector-Salaries-2021-Award-v2.pdf] Accessed: 19 Feb 2022."},{"key":"8687_CR33","unstructured":"Fair Work Ombudsman: List of Awards Fair Work Ombudsman; 2022[https:\/\/www.fairwork.gov.au\/employment-conditions\/awards\/list-of-awards] Accessed: 17 Jul 2022."},{"key":"8687_CR34","unstructured":"University of New South Wales: Oncosts associated with Salaries Kesington, NSW: University of New South Wales,; 2019[https:\/\/www.hr.unsw.edu.au\/services\/salaries\/oncosts.html] Accessed: 2 Dec 2019."},{"key":"8687_CR35","unstructured":"Australian Government Department of Health: Pharmaceutical Benefits Scheme Canberra, ACT.: Commonwealth of Australia; 2021[https:\/\/www.pbs.gov.au\/pbs\/home] Accessed: 10 Dec 2021."},{"key":"8687_CR36","unstructured":"Microsoft Corporation: Microsoft Excel 2018[https:\/\/office.microsoft.com\/excel.]"},{"issue":"1\u20132","key":"8687_CR37","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.drugalcdep.2012.12.009","volume":"131","author":"NLS Lintzeris","year":"2013","unstructured":"Lintzeris NLS, Dunlop AJ, Larance B, White N, Rivas GR, Holland RM, Degenhardt L, Muhleisen P, Hurley M, Ali R. A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence. Drug Alcohol Depend. 2013;131(1\u20132):119\u201326.","journal-title":"Drug Alcohol Depend"},{"key":"8687_CR38","unstructured":"Lintzeris N, Dunlop A, Masters D: Clinical guidelines for use of depot buprenorphine (Buvidal\u00ae and Sublocade\u00ae) in the treatment of opioid dependence Sydney Australia: NSW Ministry of Health,; 2019[https:\/\/www.health.nsw.gov.au\/aod\/Publications\/full-depot-bupe-interim-gl.pdf] Accessed."},{"issue":"1","key":"8687_CR39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/dar.12344","volume":"35","author":"B Larance","year":"2016","unstructured":"Larance B, Mattick R, Ali R, Lintzeris N, Jenkinson R, White N, Kihas I, Cassidy RLD. Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia. Drug Alcohol Rev. 2016;35(1):83\u201391.","journal-title":"Drug Alcohol Rev"},{"key":"8687_CR40","unstructured":"Queensland Health, Queensland CE: Long-Acting Injection Buprenorphine in the Treatment of Opioid Dependence Queensland Clinical Guidelines: 2019 Brisbane, Queensland; 2019[https:\/\/www.health.qld.gov.au\/__data\/assets\/pdf_file\/0032\/932684\/lai-bpn-clinical-guidelines.pdf] Accessed."}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08687-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-022-08687-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08687-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T12:12:49Z","timestamp":1701346369000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-022-08687-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["8687"],"URL":"https:\/\/doi.org\/10.1186\/s12913-022-08687-8","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,8]]},"assertion":[{"value":"16 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research trial was approved in 2018 by human research ethics committees of JHFMHN, the Aboriginal Health and Medical Research Council (AH&MRC), and CSNSW (Protocol JHFMHN File No G561\/17 & HREC\/18\/JHFMHN\/3) including this economic evaluation. The trial was registered to the Australia New Zealand Clinical Trials Registry (ANZCTR) as trial, ACTRN12618000942257, 4\/06\/2018. The research was funded by the NSW Ministry of Health. The study adhered to the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) (Additional Files). All methods were carried out in accordance with relevant guidelines and regulations. All trial participants gave voluntary and written and informed consent before the administration of any study procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Camurus AB are supplying the drug with no right of veto of publication or dissemination of results. Results will be disclosed and disseminated at the discretion of the Chief Investigator. Adrian Dunlop, Paul Haber and Nicholas Lintzeris have received funding to their institutions from Braeburn Pharmaceuticals (North American partners of Camurus AB) to support a previous and current community trial of CAM2038. No funds were provided directly to these individuals and none of the investigators or their families hold shares in Camurus or Braeburn pharmaceuticals nor stand to make financial gains through their involvement with Camurus AB.All other authors declare: no support from any organisation for the submitted work; no financial relationships with any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous 3\u00a0years; no other relationships or activities that could appear to have influenced the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1326"}}